Justin Persico, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Medical Director, Smilow Cancer Hospital at Trumbull and Fairfield
Biography
Dr. Justin Persico attended Tufts University School of Medicine where he also completed his fellowship in Hematology/Oncology. He sees patients with all types of malignancies but is also a board certified hematologist.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology & Hematology
- Medical Oncology and Hematology
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellowship
- Tufts-New England Medical Center (2012)
- Residency
- University of California - San Diego (2008)
- Internship
- University of California - San Diego (2006)
- MD
- Tufts University (2005)
Research
Publications
2021
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.Peer-Reviewed Original ResearchStromal tumor-infiltrating lymphocytesWeekly nab-paclitaxelTriple-negative breast cancerPD-L1Nab-paclitaxelAdverse eventsBreast cancerGrade 3/4 treatment-related adverse eventsPhase I/II trialGrade 3/4 adverse eventsTreatment-related adverse eventsDoxorubicin/cyclophosphamidePhase II studyGuillain-Barre syndromeMononuclear inflammatory cellsPathologic complete responseTumor-infiltrating lymphocytesTumor cell stainingEvaluable patientsNeoadjuvant durvalumabSP263 antibodyII trialNeoadjuvant chemotherapyNeoadjuvant therapyPrimary endpoint
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsA Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
HIC ID2000030007RoleSub InvestigatorPrimary Completion Date08/01/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Justin Persico, MD, specializes in medical oncology and hematology with a focus on gastrointestinal health, specifically gastrointestinal cancer diagnosis and treatment. He is the medical director of the Smilow Cancer Hospital Care Centers at Trumbull and Fairfield Connecticut.
Dr. Persico says he chose oncology as a specialty because the treatment options continue to grow and there are steady improvements in cancer outcomes. "I place a strong value on both pre-clinical and clinical research in oncology and enjoy discussing these efforts with my patients."
Dr. Persico participates in multiple research efforts including national and international clinical trials. His research interests include early onset gastrointestinal cancers, colorectal cancer, and the application of artificial intelligence in oncology.
A recipient of the Medical School House Staff Teaching Award, Dr. Persico is an assistant professor of medicine at Yale School of Medicine
Clinical Specialties
Fact Sheets
Gastrointestinal Stromal Tumors (GIST)
Learn More on Yale MedicineGestational Trophoblastic Tumors
Learn More on Yale MedicineLiver Cancer
Learn More on Yale MedicineColorectal Cancer
Learn More on Yale Medicine
Yale Medicine News
News
News
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- April 02, 2024
Yale Department of Internal Medicine Promotions and Appointments (April 2024)
- February 12, 2024
Dr. Justin Persico on Yale Cancer Answers
- August 23, 2023
Swimming while on chemotherapy and radiotherapy—a lifesaver!
Get In Touch
Contacts
Administrative Support
Locations
Smilow Cancer Hospital at Trumbull
Academic Office
5520 Park Avenue
Trumbull, CT 06611
Appointments
203.502.8400Fax
203.502.8409Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.